Paper Details

  1. Home
  2. Paper Details

Improved treatment completion with shorter treatment regimens for latent tuberculous infection.

Author: BurzynskiJ, JaleesM, LamC, MacaraigM M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A retrospective analysis of patients treated for latent tuberculous infection (LTBI) in New York City found that patients were more likely to complete treatment when offered shorter regimens (4 months of daily rifampin or 3 months of once-weekly isoniazid and rifapentine) compared to the standard 9 months of daily isoniazid.
Paper Details　
Original Abstract of the Article :
SETTING: Four New York City (NYC) Health Department tuberculosis (TB) clinics. OBJECTIVE: To assess the effectiveness of preferentially offering two shorter treatment regimens-4 months of daily rifampin (4R) and 3 months of once-weekly isoniazid and rifapentine (3HP)-as an alternative to 9 months o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/30355415

データ提供：米国国立医学図書館（NLM）

Shorter Treatment Regimens: A Key to Improved Treatment Completion for Latent TB Infection

Latent tuberculous infection (LTBI) is a significant public health concern, requiring effective treatment strategies to prevent the development of active tuberculosis. This study investigates the effectiveness of shorter treatment regimens for LTBI, comparing them to the traditional 9-month regimen. The authors conducted a retrospective analysis of patients treated for LTBI in four New York City tuberculosis clinics. The results revealed that shorter regimens, specifically 4 months of daily rifampin and 3 months of once-weekly isoniazid and rifapentine, were associated with significantly higher treatment completion rates compared to the traditional 9-month regimen. The study emphasizes the importance of encouraging community providers to use shorter regimens for LTBI treatment to reduce the TB disease burden.

Shorter Regimens: A More Effective Approach to LTBI Treatment

The study provides strong evidence supporting the use of shorter treatment regimens for LTBI. The higher treatment completion rates observed with these regimens suggest that they are more effective in preventing active tuberculosis development, contributing to a significant reduction in the TB disease burden.

Shorter Regimens: A Step Towards a Healthier Future

This research underscores the importance of adapting treatment strategies to improve patient adherence and optimize treatment outcomes. The findings highlight the potential of shorter regimens to significantly impact the fight against tuberculosis, paving the way for a healthier future.

Dr.Camel's Conclusion

This study provides compelling evidence for the effectiveness of shorter treatment regimens for latent tuberculous infection. The higher treatment completion rates observed with these regimens represent a significant step forward in preventing active tuberculosis development.

Date :
  1. Date Completed 2019-09-16
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

30355415

DOI: Digital Object Identifier

NIHMS999068

Related Literature

Article Analysis
・Side Effects of rifapentine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.